Cimeio Therapeutics

Cimeio Therapeutics

  • Founded: 2020
  • Location: Basel, Switzerland
  • Employee range: 11 - 50
  • Clinical stage: RD
  • Therapy area: Genetic diseases
  • Drug types: GEN, ONC, IMM
  • Lead product: Undisclosed
  • Product link:
  • Funding: $50M A Apr 2022

job board

Short description:

Hematopoietic stem cell transplantation and adoptive cell therapies

Drug notes:

Additional undisclosed programs RD hematologic cancers, autoimmune disorders

Long description:

Cimeio Therapeutics focuses on developing novel immunotherapies for hematologic disorders that deplete diseased cells while protecting healthy ones. Through epitope editing, they can edit a cell surface receptor to prevent antibody binding, while keeping the receptor functional. Their Shielded-Cell & Immunotherapy Pairs pipeline aims to improve patient outcomes from hemopoietic stem cell transplants. This novel cell therapy company, based in Switzerland and Boston, Massachusetts, was founded by Lukas Jeker, Professor at University of Basel.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy